

Ian Vela

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5104852/publications.pdf>

Version: 2024-02-01

16
papers

2,092
citations

687363

13
h-index

940533

16
g-index

16
all docs

16
docs citations

16
times ranked

2562
citing authors

#	ARTICLE	IF	CITATIONS
1	Urothelial Carcinoma and Prostate-specific Membrane Antigen: Cellular, Imaging, and Prognostic Implications. <i>European Urology Focus</i> , 2022, 8, 1256-1269.	3.1	4
2	Culture of Bladder Cancer Organoids as Precision Medicine Tools. <i>Journal of Visualized Experiments</i> , 2021, , .	0.3	1
3	Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2020, 77, 403-417.	1.9	614
4	Ex vivo culture of circulating tumour cells derived from non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1795-1809.	2.8	24
5	Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. <i>Lancet, The</i> , 2020, 395, 1208-1216.	13.7	1,108
6	Exploratory cost-effectiveness analysis of 68Gallium-PSMA PET/MRI-based imaging in patients with biochemical recurrence of prostate cancer. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 305-312.	3.3	28
7	Open retropubic radical prostatectomy. <i>Translational Andrology and Urology</i> , 2020, 9, 3025-3035.	1.4	3
8	A contemporary, nationwide analysis of surgery and radiotherapy treatment for prostate cancer. <i>BJU International</i> , 2019, 124, 31-36.	2.5	27
9	A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC). <i>Molecular Imaging and Biology</i> , 2019, 21, 799-807.	2.6	54
10	Stereotactic body radiotherapy for primary renal cell carcinoma and adrenal metastases. <i>Chinese Clinical Oncology</i> , 2017, 6, S17-S17.	1.2	16
11	Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease. <i>Pathology</i> , 2016, 48, 613-616.	0.6	27
12	Prostate cancer biomarkers: Are we hitting the mark?. <i>Prostate International</i> , 2016, 4, 130-135.	2.3	68
13	Metabolic Syndrome and Prostate Cancer: a Review of Complex Interplay Amongst Various Endocrine Factors in the Pathophysiology and Progression of Prostate Cancer. <i>Hormones and Cancer</i> , 2016, 7, 75-83.	4.9	25
14	Molecular Profiles of Prostate Cancer: To Treat or Not to Treat. <i>Annual Review of Medicine</i> , 2016, 67, 119-135.	12.2	15
15	Short term <i>ex-vivo</i> expansion of circulating head and neck tumour cells. <i>Oncotarget</i> , 2016, 7, 60101-60109.	1.8	48
16	Bone and prostate cancer cell interactions in metastatic prostate cancer. <i>BJU International</i> , 2007, 99, 735-742.	2.5	30